Yüklüyor......

4CPS-013 Discontinuation of sodium-glucose co-transporter 2 inhibitors due to recurrent genitourinary infections

BACKGROUND: Sodium-glucose co-transporter 2 (SGLT2) inhibitors are used in patients with type-2 diabetes (T2DM), either alone or in combination with other anti-diabetic drugs, when these medicines together with exercise and diet do not provide adequate control of the diabetes. Dapagliflozin, empagli...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Eur J Hosp Pharm
Asıl Yazarlar: Lorenzo, M Gutiérrez, Romero, L Yunquera, Lorenzo, VT, Lara, MJMorales
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Group 2018
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535808/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.104
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!